IP-Cure-B annual meeting

📢 EUCLID (EUropean CLInical Trials Platform & Development) / UMS54 MART Methods and Applied Research for Trials is attending today, 20th of November 2025, the annual meeting of the IP-Cure-B project, a European programme coordinated by Inserm , Pr Fabien Zoulim, and funded by Horizon 2020 , dedicated to developing new immunomodulatory approaches to improve the management and functional cure of chronic hepatitis B.

🌍 This final official meeting of the European consortium is an important milestone to present the progress achieved across the different Work Packages.

EUCLID (EUropean CLInical Trials Platform & Development) / UMS54 MART Methods and Applied Research for Trials is represented onsite by Pr Linda Wittkop (presenting WP2 clinical trial results), Camille Gilbert, Elodie Rouch, and Dr Christine Schwimmer.

Although this meeting marks the formal conclusion of the European project, work remains ongoing.
📈 Final analyses and trial results are expected in 2026, and the consortium stays fully committed to completing this crucial phase.

🙏 A warm thank you to Pr Maria Buti and Vall d’Hebron Barcelona Hospital Campus for their hospitality, and to all partners for their continuous commitment throughout the project